Advertisement

The Danger Hypothesis Applied to Idiosyncratic Drug Reactions

  • Jinze Li
  • Jack P. Uetrecht
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 196)

Abstract

The danger hypothesis has had a profound effect on the way immunologists view the immune response. This hypothesis proposes that the major determinant of whether an immune response is mounted against some agent is determined by whether that agent causes some type of cell damage. Assuming that most idiosyncratic drug reactions (IDRs) are immune-mediated, this hypothesis also has the potential to explain many aspects of the mechanism of these adverse drug reactions. For example, most IDRs appear to be caused by chemical metabolites rather than the parent drug, but not all drugs that form reactive metabolites are associated with a significant incidence of IDRs. Therefore, using the danger hypothesis, one feature of a drug candidate that may predict whether it causes an IDR is whether the drug, or more likely its reactive metabolites, cause cell damage. Although the range of molecules that can act as danger signals is unknown, the most attractive candidates are high mobility group box 1 protein (HMGB1), heat shock proteins, and S100 proteins. These molecules act through the same receptors (toll-like receptors) as pathogen-associated molecules that stimulate the immune system. Therefore, other environmental factors such as infections or trauma might determine which patients would be at increased risk for IDRs. Although there are examples where this appears to be the case, in most cases there are no obvious environmental factors that determine IDR risk. In addition, in animal models of immune-mediated reactions, stimulation of toll-like receptors often does not increase the immune response, and depending on the timing, it can actually be protective. Therefore, there may be additional unknown control mechanisms that are involved. A better understanding of these fundamental immune mechanisms has the potential to have a significant impact on many areas of medicine.

Keywords

HMGB1 Heat shock proteins S100 proteins Reactive metabolites Immune-mediated 

References

  1. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192:565-570PubMedCrossRefGoogle Scholar
  2. Beeler A, Engler O, Gerber BO, Pichler WJ (2006) Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 117:455-462PubMedCrossRefGoogle Scholar
  3. Benton PA, Kennedy RC (1998) DNA vaccine strategies for the treatment of cancer. Curr Top Microbiol Immunol 226:1-20PubMedCrossRefGoogle Scholar
  4. Bergmann-Leitner ES, Leitner WW (2004) Danger, death and DNA vaccines. Microb Infect 6:319-327CrossRefGoogle Scholar
  5. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1-5PubMedCrossRefGoogle Scholar
  6. Billingham RE, Brent L, Medawar PB (1953) Actively acquired tolerance of foreign cells. Nature 172:603-606PubMedCrossRefGoogle Scholar
  7. Bonney EA (2007) Preeclampsia: a view through the danger model. J Reprod Immunol 76:68-74PubMedCrossRefGoogle Scholar
  8. Bonney EA, Matzinger P (1998) Much IDO about pregnancy. Nat Med 4:1128-1129PubMedCrossRefGoogle Scholar
  9. Burnet FM (1961) Immunological recognition of self. Science 133:307-311PubMedCrossRefGoogle Scholar
  10. Calderwood SK, Mambula SS, Gray PJ Jr (2007) Extracellular heat shock proteins in cell signaling and immunity. Ann N Y Acad Sci 1113:28-39PubMedCrossRefGoogle Scholar
  11. Coutinho A, Avrameas S (1992) Speculations on immunosomatics: potential diagnostic and therapeutic value of immune homeostasis concepts. Scand J Immunol 36:527-532PubMedCrossRefGoogle Scholar
  12. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A (2007) Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther 7:1225-1241PubMedCrossRefGoogle Scholar
  13. Daskalakis G, Thomakos N, Papapanagiotou A, Liakakos T, Young RL, Antsaklis A (2004) Successful vaccine immunotherapy. An exciting novel approach to cancer treatment. Eur J Gynaecol Oncol 25:287-291PubMedGoogle Scholar
  14. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P (2007) The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 81:84-91PubMedCrossRefGoogle Scholar
  15. Ellrodt AG, Murata GH, Reidinger MS, Stewart ME, Mochizuki C, Gray R (1984) Severe neutropenia associated with sustained-release procainamide. Ann Intern Med 100:197-201PubMedGoogle Scholar
  16. Fernandez-Villar A, Sopena B, Garcia J, Gimena B, Ulloa F, Botana M, Martinez-Vazquez C (2007) Hepatitis C virus RNA in serum as a risk factor for isoniazid hepatotoxicity. Infection 35:295-297PubMedCrossRefGoogle Scholar
  17. Fischl MA, Dickinson GM, La Voie L (1988) Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. J Am Med Assoc 259:1185-1189CrossRefGoogle Scholar
  18. Foell D, Wittkowski H, Roth J (2007) Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol 3:382-390PubMedCrossRefGoogle Scholar
  19. Giarelli E (2007) Cancer vaccines: a new frontier in prevention and treatment. Oncology (Williston Park) 21:11-17; discussion 18Google Scholar
  20. Goldstein RA, Patterson R (1984) Summary. J Allergy Clin Immunol 74:643-644CrossRefGoogle Scholar
  21. Goodnow CC, Sprent J, de St F, Groth B, Vinuesa CG (2005) Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435:590-597PubMedCrossRefGoogle Scholar
  22. Gorczynski RM, Hadidi S, Yu G, Clark DA (2002) The same immunoregulatory molecules contribute to successful pregnancy and transplantation. Am J Reprod Immunol 48:18-26PubMedCrossRefGoogle Scholar
  23. Grohmann U, Fallarino F, Puccetti P (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24:242-248PubMedCrossRefGoogle Scholar
  24. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901PubMedCrossRefGoogle Scholar
  25. Hung CF, Monie A, Alvarez RD, Wu TC (2007) DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 39:679-689PubMedGoogle Scholar
  26. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, Lee SD (1997) A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 12:87-91PubMedCrossRefGoogle Scholar
  27. Janeway CA Jr (1989) The priming of helper T cells. Semin Immunol 1:13-20PubMedGoogle Scholar
  28. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29:21-32PubMedCrossRefGoogle Scholar
  29. Kimman TG, Vandebriel RJ, Hoebee B (2007) Genetic variation in the response to vaccination. Community Genet 10:201-217PubMedCrossRefGoogle Scholar
  30. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A (2008) HMGB1: endogenous danger signaling. Mol Med 14:476-484PubMedCrossRefGoogle Scholar
  31. Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF (1999) Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry 38:2312-2319PubMedCrossRefGoogle Scholar
  32. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61:1-9PubMedCrossRefGoogle Scholar
  33. Krieg AM, Vollmer J (2007) Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 220:251-269PubMedCrossRefGoogle Scholar
  34. Le Bouteiller P, Tabiasco J (2006) Immunology of pregnancy: renewed interest. Med Sci (Paris) 22:745-750CrossRefGoogle Scholar
  35. Lecoeur S, Andre C, Beaune PH (1996) Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 50:326-333PubMedGoogle Scholar
  36. Leone AM, Kao LM, McMillian MK, Nie AY, Parker JB, Kelley MF, Usuki E, Parkinson A, Lord PG, Johnson MD (2007) Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chem Res Toxicol 20:600-608PubMedCrossRefGoogle Scholar
  37. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331-342PubMedCrossRefGoogle Scholar
  38. Lu W, Uetrecht JP (2008) Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin. Drug Metab Dispos 36:1624-1636PubMedCrossRefGoogle Scholar
  39. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991-1045PubMedCrossRefGoogle Scholar
  40. Matzinger P (2007) Friendly and dangerous signals: is the tissue in control? Nat Immunol 8:11-13PubMedCrossRefGoogle Scholar
  41. Miyake K (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19:3-10PubMedCrossRefGoogle Scholar
  42. Montaner JS, Cahn P, Zala C, Casssetti LI, Losso M, Hall DB, Wruck J, McDonough M, Gigliotti M, Robinson PA (2003) Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr 33:41-46PubMedCrossRefGoogle Scholar
  43. Ochs HD, Gambineri E, Torgerson TR (2007) IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 38:112-121PubMedCrossRefGoogle Scholar
  44. Oppenheim JJ, Tewary P, de la Rosa G, Yang D (2007) Alarmins initiate host defense. Adv Exp Med Biol 601:185-194PubMedCrossRefGoogle Scholar
  45. Osterloh A, Breloer M (2008) Heat shock proteins: linking danger and pathogen recognition. Med Microbiol Immunol 197:1-8PubMedCrossRefGoogle Scholar
  46. Ozpolat B, Lachman LB (2003) Liposomal cytokines and liposomes targeted to costimulatory molecules as adjuvants for human immunodeficiency virus subunit vaccines. Methods Enzymol 373:92-100PubMedCrossRefGoogle Scholar
  47. Pacitto SR, Uetrecht JP, Boutros PC, Popovic M (2007) Changes in gene expression induced by tienilic Acid and sulfamethoxazole: testing the danger hypothesis. J Immunotoxicol 4:253-266PubMedCrossRefGoogle Scholar
  48. Park BK, Pirmohamed M, Kitteringham NR (1998) Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective. Chem Res Toxicol 11:969-988PubMedCrossRefGoogle Scholar
  49. Parker CW (1981) Hapten immunology and allergic reactions in humans. Arthritis Rheum 24:1024-1036PubMedCrossRefGoogle Scholar
  50. Parker CW (1982) Allergic reactions in man. Pharmacol Rev 34:85-104PubMedGoogle Scholar
  51. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK (2002) The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology 181-182:55-63PubMedCrossRefGoogle Scholar
  52. Power LL, Popplewell EJ, Holloway JA, Diaper ND, Warner JO, Jones CA (2002) Immunoregulatory molecules during pregnancy and at birth. J Reprod Immunol 56:19-28PubMedCrossRefGoogle Scholar
  53. Pullen H, Wright N, Murdoch J (1967) Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet 2:1176-1178PubMedCrossRefGoogle Scholar
  54. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP (1989) Diagnosis of sulfonamide hypersensitivity reactions by in-vitro “rechallenge” with hydroxylamine metabolites. Ann Intern Med 110:286-289PubMedGoogle Scholar
  55. Romagnani S (2006) Immunological tolerance and autoimmunity. Intern Emerg Med 1:187-196PubMedCrossRefGoogle Scholar
  56. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935-952PubMedCrossRefGoogle Scholar
  57. Sayeh E, Uetrecht JP (2001) Factors that modify penicillamine-induced autoimmunity in Brown Norway rats: failure of the Th1/Th2 paradigm. Toxicology 163:195-211PubMedCrossRefGoogle Scholar
  58. Schirrmaker V (2003) Improvements of survival in nine phase II clinical studies with different types of cancer upon anti-tumor vaccination with an autologous tumor cell vaccine modified by virus infection to introduce danger signals. Adv Exp Med Biol 532:175-193PubMedCrossRefGoogle Scholar
  59. Sedlmayr P (2007) Indoleamine 2, 3-dioxygenase in materno-fetal interaction. Curr Drug Metab 8:205-208PubMedCrossRefGoogle Scholar
  60. Seguin B, Uetrecht J (2003) The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 3:235-242PubMedCrossRefGoogle Scholar
  61. Shear NH, Spielberg SP (1988) Anticonvulsant hypersensitivity syndrome. J Clin Invest 82:1826-1832PubMedCrossRefGoogle Scholar
  62. Shenton JM, Chen J, Uetrecht JP (2004) Animal models of idiosyncratic drug reactions. Chem Biol Interact 150:53-70PubMedCrossRefGoogle Scholar
  63. Shenton JM, Popovic M, Chen J, Masson MJ, Uetrecht JP (2005) Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem Res Toxicol 18:1799-1813PubMedCrossRefGoogle Scholar
  64. Tarner IH, Fathman CG (2006) Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease? Nat Clin Pract Rheumatol 2:491-499PubMedCrossRefGoogle Scholar
  65. Thompson AG, Thomas R (2002) Induction of immune tolerance by dendritic cells: implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol Cell Biol 80:509-519PubMedCrossRefGoogle Scholar
  66. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8:487-496PubMedCrossRefGoogle Scholar
  67. Uetrecht JP (1999) New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol 12:387-395PubMedCrossRefGoogle Scholar
  68. Uetrecht J (2002) N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab Rev 34:651-665PubMedCrossRefGoogle Scholar
  69. Uetrecht J (2007) Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 47:513-539PubMedCrossRefGoogle Scholar
  70. Vergani D, Mieli-Vergani G, Alberti A, Neuberger J, Eddleston A, Davis M, Williams R (1980) Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med 303:66-71PubMedCrossRefGoogle Scholar
  71. von Herrath MG, Oldstone M, Homann D, Christen U (2001) Is activation of autoreactive lymphocytes always detrimental? Viral infections and regulatory circuits in autoimmunity. Curr Dir Autoimmun 4:91-122CrossRefGoogle Scholar
  72. Williams JH, Ireland HE (2008) Sensing danger - Hsp72 and HMGB1 as candidate signals. J Leukoc Biol 83:489-492PubMedCrossRefGoogle Scholar
  73. Zimmerman H (1999) Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver, 2nd edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Jinze Li
    • 1
  • Jack P. Uetrecht
  1. 1.Department of Pharmaceutical Sciences, Faculty of PharmacyUniversity of TorontoOntarioCanada

Personalised recommendations